OncoMatch/Clinical Trials/NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Is NCT04603872 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including CD19/BCMA Targeted CAR T-cells and dasatinib and CD19/BCMA Targeted CAR T-cells for multiple myeloma in relapse.
Treatment: CD19/BCMA Targeted CAR T-cells and dasatinib · CD19/BCMA Targeted CAR T-cells — A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Multiple Myeloma
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
CD19+ ALL
Required: CD19 positive
CD19+ NHL
Required: BCMA (TNFRSF17) positive
BCMA+ MM
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: car-t cell therapy
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/l
Liver function
total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal
Cardiac function
echocardiogram shows left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04603872 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior car-t cell therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify